Trifarotene

Trifarotene, sold under the brand name Aklief, is for the topical treatment of acne vulgaris in those nine years of age and older.[1] It is a retinoid.[2]

Trifarotene
Clinical data
Trade namesAklief
Other namesCD5789
AHFS/Drugs.comMonograph
License data
Routes of
administration		Topical
Drug classSkin and mucous membrane agents
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H33NO4
Molar mass459.586 g·mol−1
3D model (JSmol)

It was approved for medical use in the United States in 2019.[1][3][4]

References
  1. "Drug Trials Snapshots: Aklief". U.S. Food and Drug Administration (FDA). 11 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
  2. Trifarotene Monograph
  3. "Aklief (trifarotene) FDA Approval History". Drugs.com. 7 October 2019. Retrieved 19 November 2019.
  4. "Drug Approval Package: Aklief". U.S. Food and Drug Administration (FDA). 21 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.
  • "Trifarotene". Drug Information Portal. U.S. National Library of Medicine (NLM).


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.